NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder litigation firm, alerts investors that it is investigating whether GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION
GeneDx performs genetic tests for rare diseases, such as whole exome and genome tests (“E&G tests”). In the last two years, the Company has more than doubled the volume of E&G tests performed each quarter, and quarterly revenue from E&G tests has more than tripled.
On February 5, 2025, Grizzly Research, a short seller, released a report (the “Report”) in which a former GeneDx employee alleged that the Company had engaged in an illegal practice known as “code stacking,” by which the Company billed insurers for additional services the Company did not perform. The Report also alleged that code stacking inflated the Company’s revenue by 25%. On this news, the price of the Company’s stock fell $4.84, or nearly 7%, to close at $67.18 on February 5, 2025.
On April 30, 2025, the Company released its 1Q25 financial results, reporting that—for the first time in eight quarters—the Company’s E&G test volume and revenue were flat. On this news, the price of the Company’s stock fell $50.12, or nearly 43%, to close at $66.85 on April 30, 2025.
ARE YOU A POTENTIAL CLASS MEMBER ELIGIBLE TO RECOVER? CLICK HERE
If you have purchased GeneDx securities, and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Nicholas Bruno at (888) 398-9312 or at nbruno@scott-scott.com.
CLICK HERE TO FIND OUT IF YOU CAN RECOVER YOUR LOSSES
About Scott+Scott
Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoing, including securities law and shareholder violations. With more than 100 attorneys in eight offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been repeatedly recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States.
This may be considered Attorney Advertising.
CONTACT:
Nicholas Bruno
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 24th Floor, New York, NY 10169
(888) 398-9312
nbruno@scott-scott.com
